Dimerix Ltd has released a press release.
Adolescent Recruitment into ACTION3 Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Dimerix
- Dimerix and Taiba enter into License Agreement for DMX-200
- Dimerix Receives PIP Approval from the UK MHRA
- Dimerix Completes $20M Placement
- Dimerix Successfully Passes Efficacy Interim Analysis
- PH3 Data Collection Complete for First Interim Analysis
Later from Dimerix
- Preliminary Final Report
- First patient enters into Open Label Extension study
- First Paediatric Site Activated and Trial Update
- ACTION3 Trial Recruitment and Multiregion Trial Site Update
- Project PARASOL Update & Medical Advisory Board Appointment
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix